カテゴリ： 世界, 医療/バイオ, Market Monitor Global

下垂体ACTH過剰分泌薬のグローバル市場展望 2023年-2029年：AT-814、ATR-101、BIM-23A758、COR-005、CORT-125134、ISIS-GCCRRx、その他

■ 英語タイトル：Pituitary ACTH Hypersecretion Drug Market, Global Outlook and Forecast 2023-2029

調査会社Market Monitor Global社が発行したリサーチレポート（データ管理コード：MMG23LY8558）■ 発行会社/調査会社：Market Monitor Global
■ 商品コード：MMG23LY8558
■ 発行日：2023年7月
■ 調査対象地域：グローバル、北米、アメリカ、ヨーロッパ、アジア、日本、中国、東南アジア、インド、南米、中東・アフリカなど
■ 産業分野：医薬品＆ヘルスケア
■ ページ数：72
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（受注後2-3営業日）
■ 販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,250 ⇒換算￥494,000見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）USD4,225 ⇒換算￥642,200見積依頼/購入/質問フォーム
Enterprise User（閲覧人数制限なし）USD4,875 ⇒換算￥741,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※Market Monitor Global社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[下垂体ACTH過剰分泌薬のグローバル市場展望 2023年-2029年：AT-814、ATR-101、BIM-23A758、COR-005、CORT-125134、ISIS-GCCRRx、その他]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

当調査レポートは次の情報を含め、世界の下垂体ACTH過剰分泌薬市場規模と予測を収録しています。・世界の下垂体ACTH過剰分泌薬市場：売上、2018年-2023年、2024年-2029年
・世界の下垂体ACTH過剰分泌薬市場：販売量、2018年-2023年、2024年-2029年
・世界のトップ5企業、2022年

世界の下垂体ACTH過剰分泌薬市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。米国市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「AT-814」セグメントは今後6年間、000%のCAGRで2029年までに000Mドルに成長すると予測されています。

下垂体ACTH過剰分泌薬のグローバル主要企業は、Alder Biopharmaceuticals Inc.、 Corcept Therapeutics Incorporated、 Cortendo AB、 Cyclacel Pharmaceuticals, Inc.、 ElexoPharm GmbH、 Ipsen S.A.、 Isis Pharmaceuticals, Inc.、 Novartis AG、 Orphagen Pharmaceuticals, Inc.、 Pfizer Inc.などです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。

MARKET MONITOR GLOBAL（MMG）は、下垂体ACTH過剰分泌薬のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。

【セグメント別市場分析】

世界の下垂体ACTH過剰分泌薬市場：タイプ別、2018年-2023年、2024年-2029年
世界の下垂体ACTH過剰分泌薬市場：タイプ別市場シェア、2022年
・AT-814、ATR-101、BIM-23A758、COR-005、CORT-125134、ISIS-GCCRRx、その他

世界の下垂体ACTH過剰分泌薬市場：用途別、2018年-2023年、2024年-2029年
世界の下垂体ACTH過剰分泌薬市場：用途別市場シェア、2022年
・診療所、病院、その他

世界の下垂体ACTH過剰分泌薬市場：地域・国別、2018年-2023年、2024年-2029年
世界の下垂体ACTH過剰分泌薬市場：地域別市場シェア、2022年
・北米：アメリカ、カナダ、メキシコ
・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア
・アジア：中国、日本、韓国、東南アジア、インド
・南米：ブラジル、アルゼンチン
・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE

【競合分析】

また、当レポートは主要な市場参加者の分析を提供します。
・主要企業における下垂体ACTH過剰分泌薬のグローバル売上、2018年-2023年
・主要企業における下垂体ACTH過剰分泌薬のグローバル売上シェア、2022年
・主要企業における下垂体ACTH過剰分泌薬のグローバル販売量、2018年-2023年
・主要企業における下垂体ACTH過剰分泌薬のグローバル販売量シェア、2022年

さらに、当レポートは主要企業のプロファイルを提示します。
Alder Biopharmaceuticals Inc.、 Corcept Therapeutics Incorporated、 Cortendo AB、 Cyclacel Pharmaceuticals, Inc.、 ElexoPharm GmbH、 Ipsen S.A.、 Isis Pharmaceuticals, Inc.、 Novartis AG、 Orphagen Pharmaceuticals, Inc.、 Pfizer Inc.

*************************************************************

・調査・分析レポートの概要
下垂体ACTH過剰分泌薬市場の定義
市場セグメント
世界の下垂体ACTH過剰分泌薬市場概要
当レポートの特徴・ベネフィット
調査手法と情報源

・世界の下垂体ACTH過剰分泌薬市場規模
世界の下垂体ACTH過剰分泌薬市場規模：2022年 VS 2029年
世界の下垂体ACTH過剰分泌薬市場規模と予測 2018年-2029年

・競争状況
グローバルトップ企業
売上ベースでのグローバルトップ企業
企業別グローバルでの下垂体ACTH過剰分泌薬の売上
グローバルトップ3およびトップ5企業、2022年売上ベース
グローバル企業の下垂体ACTH過剰分泌薬製品タイプ
グローバルにおけるティア1、ティア2、ティア3企業

・タイプ別市場分析
タイプ区分：AT-814、ATR-101、BIM-23A758、COR-005、CORT-125134、ISIS-GCCRRx、その他
下垂体ACTH過剰分泌薬のタイプ別グローバル売上・予測

・用途別市場分析
用途区分：診療所、病院、その他
下垂体ACTH過剰分泌薬の用途別グローバル売上・予測

・地域別市場分析
地域別下垂体ACTH過剰分泌薬市場規模 2022年と2029年
地域別下垂体ACTH過剰分泌薬売上・予測
北米市場：アメリカ、カナダ、メキシコ
ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア
アジア市場：中国、日本、韓国、東南アジア、インド
南米市場：ブラジル、アルゼンチン
中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE

・主要企業のプロファイル（企業概要、事業概要、主要製品、売上、ニュースなど）
Alder Biopharmaceuticals Inc.、 Corcept Therapeutics Incorporated、 Cortendo AB、 Cyclacel Pharmaceuticals, Inc.、 ElexoPharm GmbH、 Ipsen S.A.、 Isis Pharmaceuticals, Inc.、 Novartis AG、 Orphagen Pharmaceuticals, Inc.、 Pfizer Inc.
...

This report aims to provide a comprehensive presentation of the global market for Pituitary ACTH Hypersecretion Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Pituitary ACTH Hypersecretion Drug. This report contains market size and forecasts of Pituitary ACTH Hypersecretion Drug in global, including the following market information:
Global Pituitary ACTH Hypersecretion Drug Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global Pituitary ACTH Hypersecretion Drug Market Sales, 2018-2023, 2024-2029, (K Pcs)
Global top five Pituitary ACTH Hypersecretion Drug companies in 2022 (%)
The global Pituitary ACTH Hypersecretion Drug market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is Forecast to Reach $ Million.
AT-814 Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Pituitary ACTH Hypersecretion Drug include Alder Biopharmaceuticals Inc., Corcept Therapeutics Incorporated, Cortendo AB, Cyclacel Pharmaceuticals, Inc., ElexoPharm GmbH, Ipsen S.A., Isis Pharmaceuticals, Inc., Novartis AG and Orphagen Pharmaceuticals, Inc., etc. in 2022, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Pituitary ACTH Hypersecretion Drug manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Pituitary ACTH Hypersecretion Drug Market, by Type, 2018-2023, 2024-2029 ($ Millions) & (K Pcs)
Global Pituitary ACTH Hypersecretion Drug Market Segment Percentages, by Type, 2022 (%)
AT-814
ATR-101
BIM-23A758
COR-005
CORT-125134
ISIS-GCCRRx
Others
Global Pituitary ACTH Hypersecretion Drug Market, by Application, 2018-2023, 2024-2029 ($ Millions) & (K Pcs)
Global Pituitary ACTH Hypersecretion Drug Market Segment Percentages, by Application, 2022 (%)
Clinic
Hospital
Others
Global Pituitary ACTH Hypersecretion Drug Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions) & (K Pcs)
Global Pituitary ACTH Hypersecretion Drug Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Pituitary ACTH Hypersecretion Drug revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Pituitary ACTH Hypersecretion Drug revenues share in global market, 2022 (%)
Key companies Pituitary ACTH Hypersecretion Drug sales in global market, 2018-2023 (Estimated), (K Pcs)
Key companies Pituitary ACTH Hypersecretion Drug sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Alder Biopharmaceuticals Inc.
Corcept Therapeutics Incorporated
Cortendo AB
Cyclacel Pharmaceuticals, Inc.
ElexoPharm GmbH
Ipsen S.A.
Isis Pharmaceuticals, Inc.
Novartis AG
Orphagen Pharmaceuticals, Inc.
Pfizer Inc.
Outline of Major Chapters:
Chapter 1: Introduces the definition of Pituitary ACTH Hypersecretion Drug, market overview.
Chapter 2: Global Pituitary ACTH Hypersecretion Drug market size in revenue and volume.
Chapter 3: Detailed analysis of Pituitary ACTH Hypersecretion Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Pituitary ACTH Hypersecretion Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Pituitary ACTH Hypersecretion Drug capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.

*** レポート目次（コンテンツ）***

1 Introduction to Research & Analysis Reports
1.1 Pituitary ACTH Hypersecretion Drug Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Pituitary ACTH Hypersecretion Drug Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Pituitary ACTH Hypersecretion Drug Overall Market Size
2.1 Global Pituitary ACTH Hypersecretion Drug Market Size: 2022 VS 2029
2.2 Global Pituitary ACTH Hypersecretion Drug Revenue, Prospects & Forecasts: 2018-2029
2.3 Global Pituitary ACTH Hypersecretion Drug Sales: 2018-2029
3 Company Landscape
3.1 Top Pituitary ACTH Hypersecretion Drug Players in Global Market
3.2 Top Global Pituitary ACTH Hypersecretion Drug Companies Ranked by Revenue
3.3 Global Pituitary ACTH Hypersecretion Drug Revenue by Companies
3.4 Global Pituitary ACTH Hypersecretion Drug Sales by Companies
3.5 Global Pituitary ACTH Hypersecretion Drug Price by Manufacturer (2018-2023)
3.6 Top 3 and Top 5 Pituitary ACTH Hypersecretion Drug Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers Pituitary ACTH Hypersecretion Drug Product Type
3.8 Tier 1, Tier 2 and Tier 3 Pituitary ACTH Hypersecretion Drug Players in Global Market
3.8.1 List of Global Tier 1 Pituitary ACTH Hypersecretion Drug Companies
3.8.2 List of Global Tier 2 and Tier 3 Pituitary ACTH Hypersecretion Drug Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type – Global Pituitary ACTH Hypersecretion Drug Market Size Markets, 2022 & 2029
4.1.2 AT-814
4.1.3 ATR-101
4.1.4 BIM-23A758
4.1.5 COR-005
4.1.6 CORT-125134
4.1.7 ISIS-GCCRRx
4.1.8 Others
4.2 By Type – Global Pituitary ACTH Hypersecretion Drug Revenue & Forecasts
4.2.1 By Type – Global Pituitary ACTH Hypersecretion Drug Revenue, 2018-2023
4.2.2 By Type – Global Pituitary ACTH Hypersecretion Drug Revenue, 2024-2029
4.2.3 By Type – Global Pituitary ACTH Hypersecretion Drug Revenue Market Share, 2018-2029
4.3 By Type – Global Pituitary ACTH Hypersecretion Drug Sales & Forecasts
4.3.1 By Type – Global Pituitary ACTH Hypersecretion Drug Sales, 2018-2023
4.3.2 By Type – Global Pituitary ACTH Hypersecretion Drug Sales, 2024-2029
4.3.3 By Type – Global Pituitary ACTH Hypersecretion Drug Sales Market Share, 2018-2029
4.4 By Type – Global Pituitary ACTH Hypersecretion Drug Price (Manufacturers Selling Prices), 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Pituitary ACTH Hypersecretion Drug Market Size, 2022 & 2029
5.1.2 Clinic
5.1.3 Hospital
5.1.4 Others
5.2 By Application – Global Pituitary ACTH Hypersecretion Drug Revenue & Forecasts
5.2.1 By Application – Global Pituitary ACTH Hypersecretion Drug Revenue, 2018-2023
5.2.2 By Application – Global Pituitary ACTH Hypersecretion Drug Revenue, 2024-2029
5.2.3 By Application – Global Pituitary ACTH Hypersecretion Drug Revenue Market Share, 2018-2029
5.3 By Application – Global Pituitary ACTH Hypersecretion Drug Sales & Forecasts
5.3.1 By Application – Global Pituitary ACTH Hypersecretion Drug Sales, 2018-2023
5.3.2 By Application – Global Pituitary ACTH Hypersecretion Drug Sales, 2024-2029
5.3.3 By Application – Global Pituitary ACTH Hypersecretion Drug Sales Market Share, 2018-2029
5.4 By Application – Global Pituitary ACTH Hypersecretion Drug Price (Manufacturers Selling Prices), 2018-2029
6 Sights by Region
6.1 By Region – Global Pituitary ACTH Hypersecretion Drug Market Size, 2022 & 2029
6.2 By Region – Global Pituitary ACTH Hypersecretion Drug Revenue & Forecasts
6.2.1 By Region – Global Pituitary ACTH Hypersecretion Drug Revenue, 2018-2023
6.2.2 By Region – Global Pituitary ACTH Hypersecretion Drug Revenue, 2024-2029
6.2.3 By Region – Global Pituitary ACTH Hypersecretion Drug Revenue Market Share, 2018-2029
6.3 By Region – Global Pituitary ACTH Hypersecretion Drug Sales & Forecasts
6.3.1 By Region – Global Pituitary ACTH Hypersecretion Drug Sales, 2018-2023
6.3.2 By Region – Global Pituitary ACTH Hypersecretion Drug Sales, 2024-2029
6.3.3 By Region – Global Pituitary ACTH Hypersecretion Drug Sales Market Share, 2018-2029
6.4 North America
6.4.1 By Country – North America Pituitary ACTH Hypersecretion Drug Revenue, 2018-2029
6.4.2 By Country – North America Pituitary ACTH Hypersecretion Drug Sales, 2018-2029
6.4.3 US Pituitary ACTH Hypersecretion Drug Market Size, 2018-2029
6.4.4 Canada Pituitary ACTH Hypersecretion Drug Market Size, 2018-2029
6.4.5 Mexico Pituitary ACTH Hypersecretion Drug Market Size, 2018-2029
6.5 Europe
6.5.1 By Country – Europe Pituitary ACTH Hypersecretion Drug Revenue, 2018-2029
6.5.2 By Country – Europe Pituitary ACTH Hypersecretion Drug Sales, 2018-2029
6.5.3 Germany Pituitary ACTH Hypersecretion Drug Market Size, 2018-2029
6.5.4 France Pituitary ACTH Hypersecretion Drug Market Size, 2018-2029
6.5.5 U.K. Pituitary ACTH Hypersecretion Drug Market Size, 2018-2029
6.5.6 Italy Pituitary ACTH Hypersecretion Drug Market Size, 2018-2029
6.5.7 Russia Pituitary ACTH Hypersecretion Drug Market Size, 2018-2029
6.5.8 Nordic Countries Pituitary ACTH Hypersecretion Drug Market Size, 2018-2029
6.5.9 Benelux Pituitary ACTH Hypersecretion Drug Market Size, 2018-2029
6.6 Asia
6.6.1 By Region – Asia Pituitary ACTH Hypersecretion Drug Revenue, 2018-2029
6.6.2 By Region – Asia Pituitary ACTH Hypersecretion Drug Sales, 2018-2029
6.6.3 China Pituitary ACTH Hypersecretion Drug Market Size, 2018-2029
6.6.4 Japan Pituitary ACTH Hypersecretion Drug Market Size, 2018-2029
6.6.5 South Korea Pituitary ACTH Hypersecretion Drug Market Size, 2018-2029
6.6.6 Southeast Asia Pituitary ACTH Hypersecretion Drug Market Size, 2018-2029
6.6.7 India Pituitary ACTH Hypersecretion Drug Market Size, 2018-2029
6.7 South America
6.7.1 By Country – South America Pituitary ACTH Hypersecretion Drug Revenue, 2018-2029
6.7.2 By Country – South America Pituitary ACTH Hypersecretion Drug Sales, 2018-2029
6.7.3 Brazil Pituitary ACTH Hypersecretion Drug Market Size, 2018-2029
6.7.4 Argentina Pituitary ACTH Hypersecretion Drug Market Size, 2018-2029
6.8 Middle East & Africa
6.8.1 By Country – Middle East & Africa Pituitary ACTH Hypersecretion Drug Revenue, 2018-2029
6.8.2 By Country – Middle East & Africa Pituitary ACTH Hypersecretion Drug Sales, 2018-2029
6.8.3 Turkey Pituitary ACTH Hypersecretion Drug Market Size, 2018-2029
6.8.4 Israel Pituitary ACTH Hypersecretion Drug Market Size, 2018-2029
6.8.5 Saudi Arabia Pituitary ACTH Hypersecretion Drug Market Size, 2018-2029
6.8.6 UAE Pituitary ACTH Hypersecretion Drug Market Size, 2018-2029
7 Manufacturers & Brands Profiles
7.1 Alder Biopharmaceuticals Inc.
7.1.1 Alder Biopharmaceuticals Inc. Company Summary
7.1.2 Alder Biopharmaceuticals Inc. Business Overview
7.1.3 Alder Biopharmaceuticals Inc. Pituitary ACTH Hypersecretion Drug Major Product Offerings
7.1.4 Alder Biopharmaceuticals Inc. Pituitary ACTH Hypersecretion Drug Sales and Revenue in Global (2018-2023)
7.1.5 Alder Biopharmaceuticals Inc. Key News & Latest Developments
7.2 Corcept Therapeutics Incorporated
7.2.1 Corcept Therapeutics Incorporated Company Summary
7.2.2 Corcept Therapeutics Incorporated Business Overview
7.2.3 Corcept Therapeutics Incorporated Pituitary ACTH Hypersecretion Drug Major Product Offerings
7.2.4 Corcept Therapeutics Incorporated Pituitary ACTH Hypersecretion Drug Sales and Revenue in Global (2018-2023)
7.2.5 Corcept Therapeutics Incorporated Key News & Latest Developments
7.3 Cortendo AB
7.3.1 Cortendo AB Company Summary
7.3.2 Cortendo AB Business Overview
7.3.3 Cortendo AB Pituitary ACTH Hypersecretion Drug Major Product Offerings
7.3.4 Cortendo AB Pituitary ACTH Hypersecretion Drug Sales and Revenue in Global (2018-2023)
7.3.5 Cortendo AB Key News & Latest Developments
7.4 Cyclacel Pharmaceuticals, Inc.
7.4.1 Cyclacel Pharmaceuticals, Inc. Company Summary
7.4.2 Cyclacel Pharmaceuticals, Inc. Business Overview
7.4.3 Cyclacel Pharmaceuticals, Inc. Pituitary ACTH Hypersecretion Drug Major Product Offerings
7.4.4 Cyclacel Pharmaceuticals, Inc. Pituitary ACTH Hypersecretion Drug Sales and Revenue in Global (2018-2023)
7.4.5 Cyclacel Pharmaceuticals, Inc. Key News & Latest Developments
7.5 ElexoPharm GmbH
7.5.1 ElexoPharm GmbH Company Summary
7.5.2 ElexoPharm GmbH Business Overview
7.5.3 ElexoPharm GmbH Pituitary ACTH Hypersecretion Drug Major Product Offerings
7.5.4 ElexoPharm GmbH Pituitary ACTH Hypersecretion Drug Sales and Revenue in Global (2018-2023)
7.5.5 ElexoPharm GmbH Key News & Latest Developments
7.6 Ipsen S.A.
7.6.1 Ipsen S.A. Company Summary
7.6.2 Ipsen S.A. Business Overview
7.6.3 Ipsen S.A. Pituitary ACTH Hypersecretion Drug Major Product Offerings
7.6.4 Ipsen S.A. Pituitary ACTH Hypersecretion Drug Sales and Revenue in Global (2018-2023)
7.6.5 Ipsen S.A. Key News & Latest Developments
7.7 Isis Pharmaceuticals, Inc.
7.7.1 Isis Pharmaceuticals, Inc. Company Summary
7.7.2 Isis Pharmaceuticals, Inc. Business Overview
7.7.3 Isis Pharmaceuticals, Inc. Pituitary ACTH Hypersecretion Drug Major Product Offerings
7.7.4 Isis Pharmaceuticals, Inc. Pituitary ACTH Hypersecretion Drug Sales and Revenue in Global (2018-2023)
7.7.5 Isis Pharmaceuticals, Inc. Key News & Latest Developments
7.8 Novartis AG
7.8.1 Novartis AG Company Summary
7.8.2 Novartis AG Business Overview
7.8.3 Novartis AG Pituitary ACTH Hypersecretion Drug Major Product Offerings
7.8.4 Novartis AG Pituitary ACTH Hypersecretion Drug Sales and Revenue in Global (2018-2023)
7.8.5 Novartis AG Key News & Latest Developments
7.9 Orphagen Pharmaceuticals, Inc.
7.9.1 Orphagen Pharmaceuticals, Inc. Company Summary
7.9.2 Orphagen Pharmaceuticals, Inc. Business Overview
7.9.3 Orphagen Pharmaceuticals, Inc. Pituitary ACTH Hypersecretion Drug Major Product Offerings
7.9.4 Orphagen Pharmaceuticals, Inc. Pituitary ACTH Hypersecretion Drug Sales and Revenue in Global (2018-2023)
7.9.5 Orphagen Pharmaceuticals, Inc. Key News & Latest Developments
7.10 Pfizer Inc.
7.10.1 Pfizer Inc. Company Summary
7.10.2 Pfizer Inc. Business Overview
7.10.3 Pfizer Inc. Pituitary ACTH Hypersecretion Drug Major Product Offerings
7.10.4 Pfizer Inc. Pituitary ACTH Hypersecretion Drug Sales and Revenue in Global (2018-2023)
7.10.5 Pfizer Inc. Key News & Latest Developments
8 Global Pituitary ACTH Hypersecretion Drug Production Capacity, Analysis
8.1 Global Pituitary ACTH Hypersecretion Drug Production Capacity, 2018-2029
8.2 Pituitary ACTH Hypersecretion Drug Production Capacity of Key Manufacturers in Global Market
8.3 Global Pituitary ACTH Hypersecretion Drug Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Pituitary ACTH Hypersecretion Drug Supply Chain Analysis
10.1 Pituitary ACTH Hypersecretion Drug Industry Value Chain
10.2 Pituitary ACTH Hypersecretion Drug Upstream Market
10.3 Pituitary ACTH Hypersecretion Drug Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Pituitary ACTH Hypersecretion Drug Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer



*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • I型高リポタンパク血症治療薬のグローバル市場展望 2023年-2029年：アリポジーンティパルボベク、CAT-2003、ISIS-APOCIIIRx、メシル酸ロミタピド、プラディガスタットナトリウム、その他
  • 世界の副腎皮質刺激ホルモン(ACTH)市場2022年：市場規模予測（～2028年）
  • 高シュウ酸尿症一次治療薬のグローバル市場展望 2023年-2029年：ALLN-230、DCR-PHXC、ALN-GO1、その他
  • 運動促進薬のグローバル市場展望 2023年-2029年：メトクロプラミド、ドンペリドン、シサプリド、その他
  • 二重抗体薬のグローバル市場展望 2023年-2029年：レモバブ、BLINCYTO、その他
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(MMG23LY8558 )"下垂体ACTH過剰分泌薬のグローバル市場展望 2023年-2029年：AT-814、ATR-101、BIM-23A758、COR-005、CORT-125134、ISIS-GCCRRx、その他" (英文：Pituitary ACTH Hypersecretion Drug Market, Global Outlook and Forecast 2023-2029)はMarket Monitor Global社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。